

1 **Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory**
2 **functions and clearance of apoptotic cells**

3
4 Ana C. G. Salina^{1†}, Douglas dos-Santos^{1†}, Tamara S. Rodrigues^{1†}, Marlon Fortes-Rocha¹,
5 Edismauro G. Freitas-Filho¹, Daniel L. Alzamora-Terrel¹, Ícaro M. S. Castro², Thais F. C. Fraga
6 da Silva³, Mikhael H. F. de Lima⁴, Daniele C. Nascimento⁴, Camila M. Silva⁴, Juliana E. Toller-
7 Kawahisa⁴, Amanda Becerra¹, Samuel Oliveira¹, Diego B. Caetité⁴, Leticia Almeida^{1,5}, Adriene
8 Y. Ishimoto¹, Thais M. Lima¹, Ronaldo B. Martins¹, Flavio Veras^{4,5}, Natália B. do Amaral⁶,
9 Marcela C. Giannini⁶, Leticia P. Bonjorno⁶, Maria I. F. Lopes⁶, Maira N. Benatti⁸, Sabrina S.
10 Batah⁸, Rodrigo C. Santana⁶, Fernando C. Vilar⁶, Maria A. Martins⁷, Rodrigo L. Assad⁶, Sergio
11 C. L. de Almeida⁶, Fabiola R. de Oliveira⁶, Eurico Arruda Neto¹, Thiago M. Cunha^{4,5}, José C.
12 Alves-Filho^{4,5}, Vânia L. D. Bonato³, Fernando Q. Cunha^{4,5}, Alexandre T. Fabro⁸, Helder I.
13 Nakaya^{2,5}, Dario S. Zamboni^{1,5}, Paulo Louzada-Junior^{5,6}, Rene D. R. Oliveira⁶, Larissa D.
14 Cunha^{1*}

15
16
17 ¹Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de
18 Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

19 ²Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas,
20 Universidade de São Paulo, Brazil.

21 ³Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto,
22 Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.

23 ⁴Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São
24 Paulo, Ribeirão Preto, São Paulo, Brazil.

25 ⁵Center of Research in Inflammatory Diseases (CRID), Faculdade de Medicina de Ribeirão
26 Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.

27 ⁶Divisão de Imunologia Clínica, Emergência, Doenças Infecciosas e Unidade de Terapia
28 Intensiva, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto,
29 SP, Brazil.

30 ⁷Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade
31 de São Paulo, Ribeirão Preto, SP, Brazil.

32 ⁸Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto,
33 Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

34
35 † A.C.G.S., D.S., and T.S.R. equally contributed to this work.

36
37 * Correspondence: Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos
38 Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
39 Av. Bandeirantes 3900, Ribeirão Preto, SP 14049-900, Brazil
40 Tel: +55 16 33153319
41 larissacunha@usp.br
42 (ORCID iD: 0000-0002-1290-0263),
43
44

45 **Abstract**

46

47 COVID-19 is a disease of dysfunctional immune responses, but the mechanisms triggering
48 immunopathogenesis are not established. The functional plasticity of macrophages allows this
49 cell type to promote pathogen elimination and inflammation or suppress inflammation and
50 promote tissue remodeling and injury repair. During an infection, the clearance of dead and
51 dying cells, a process named efferocytosis, can modulate the interplay between these contrasting
52 functions. Here, we show that engulfment of SARS-CoV2-infected apoptotic cells exacerbates
53 inflammatory cytokine production, inhibits the expression of efferocytic receptors, and impairs
54 continual efferocytosis by macrophages. We also provide evidence supporting that lung
55 monocytes and macrophages from severe COVID-19 patients have compromised efferocytic
56 capacity. Our findings reveal that dysfunctional efferocytosis of SARS-CoV-2-infected cell
57 corpses suppress macrophage anti-inflammation and efficient tissue repair programs and provide
58 mechanistic insights for the excessive production of pro-inflammatory cytokines and
59 accumulation of tissue damage associated with COVID-19 immunopathogenesis.

60

61

62 **KEYWORDS: COVID-19, macrophage, macrophage polarization, efferocytosis,**
63 **hyperinflammation, tissue repair**

64

65

66

67

68 **Introduction**

69

70 Patients with severe and critical COVID-19 progress from pneumonia to development of acute
71 respiratory distress syndrome (ARDS) and respiratory failure, septic shock, and multiorgan
72 dysfunction (Siddiqi and Mehra, 2020). These severe clinical manifestations of the disease are
73 caused by dysregulated host immune response, including compromised function of the myeloid
74 compartment (Blanco-Melo et al., 2020; Lucas et al., 2020; Rodrigues et al., 2020; Schulte-
75 Schrepping et al., 2020; Silvin et al., 2020; Valle et al., 2020; Veras et al., 2020). Therefore,
76 hyperinflammation and extensive unresolved tissue damage associated with dysfunctional innate
77 responses should contribute to the pathogenesis of inflammatory lung disease and worsening of
78 COVID-19, although underlying mechanisms are still loosely defined.

79

80 Macrophages and monocytes are functionally plastic cells that can promote homeostasis and
81 resolution of inflammation by sensing microbial and host-derived signals and programming their
82 gene expression toward an anti-inflammatory, pro-resolution, and wound-healing phenotype
83 (Martins et al., 2019; (Trzebanski and Jung, 2020). This host-protective programming reduces
84 inflammatory cytokine production by other immune and non-immune cells and promotes the
85 repair of damaged tissue to sustain physiological function and re-establish homeostasis (Murray
86 and Wynn, 2011). During the repair process, the efficient clearance of dying cells prevents
87 further tissue dysfunction caused by uncontrolled cytotoxicity and the release of damage-
88 associated molecular patterns (DAMP). Defects in sensing, ingesting, and degradation of dead
89 and dying cells through efferocytosis cause chronic inflammation and autoimmune diseases
90 (Boada-Romero et al., 2020). In addition to preventing the deleterious effects of secondary

91 necrosis, efferocytosis also couples corpse internalization to other environmental cues (such as
92 local cytokines and metabolites) to temporally and spatially regulate macrophage anti-
93 inflammatory and tissue repair functions (A-Gonzalez et al., 2017; Bosurgi et al., 2017; Perry et
94 al., 2019). While the clearance of apoptotic cells is often associated with alternative macrophage
95 programming, the identity of the dying cell, the type of cell death, and the context of death
96 (either sterile or infectious) can modulate the nature of the macrophage response (Rothlin et al.,
97 2020).

98
99 While infection with SARS-CoV2 induces the recruitment of immune cells to the lungs, their
100 role in host defense and the causes for the dysfunction during disease progression remain elusive.
101 Here, we sought to determine how macrophages operate when responding to dying epithelial
102 cells infected with SARS-CoV-2. We found that the presence of viable SARS-CoV-2 in cell
103 corpses dysregulates macrophage anti-inflammatory responses to the efferocytosis of apoptotic
104 cells, promoting excessive production of inflammatory IL-6 and IL-1 β while disrupting the
105 efficient continual clearance of dead cells required for effective tissue repair. We also provide
106 evidence that the expression of efferocytic genes is reduced in macrophages from severe
107 COVID-19 patients. Therefore, SARS-CoV-2 infection and the clearance of infected dying cells
108 disrupt macrophage host-protective functions associated with immunopathological
109 manifestations of COVID-19.

110

111 **Results**

112

113 **Macrophages engulf dying cells carrying viable SARS-CoV-2**

114

115 SARS-CoV-2 infection causes cytopathic effects in human and primate epithelial cells (Chu et
116 al., 2020; Zhu et al., 2020), possibly mediated by activation of multiple cell death pathways
117 (Chan et al., 2020; Shaohua Li et al., 2020; Shufen Li et al., 2020; Mulay et al., 2021; Ren et al.,
118 2020; Zhu et al., 2020). Notably, inhibition of apoptosis ameliorates cytokine expression and
119 tissue damage in the lungs of SARS-CoV-2-infected mice, indicating that apoptosis in the lungs
120 is pathogenic (Chu et al., 2021). Agreeing with previous reports (Chu et al., 2020; Ren et al.,
121 2020; Zhu et al., 2020), infection with SARS-CoV-2 for 48 hours induced caspase-3 and
122 caspase-8 activation in immortalized simian kidney epithelial Vero CCL81 (**Figure 1A**) and
123 human lung epithelial Calu-3 cell lines (**Figures 1A and B**). We also found features consistent
124 with the predominance of apoptotic cell death at 48 h post-infection by flow cytometric analysis
125 of the pattern of annexin V and a permeability dye co-staining in infected cells (**Figure 1C**).
126 Consistently, we observed low levels of cytolysis in these infected cells, as assessed by lactate
127 dehydrogenase release (**Figure 1D**). Immunofluorescent labeling of cleaved caspase-3 in lung
128 tissues of deceased COVID-19 patients confirmed the induction of apoptosis in the epithelia
129 infected with replicant SARS-CoV-2 (**Figure 1E**, and **Figure 1 – figure supplement 1A**).
130 Examination of lung tissues also revealed evidence of macrophages with internalized epithelial
131 cells and SARS-CoV-2, suggesting the uptake of infected epithelial cells by macrophages
132 (**Figure 1F**).

133

134 We performed the Median Tissue Culture Infection Dose (TCID₅₀) assay and found that viral
135 particles obtained from isolated apoptotic Vero and Calu-3 cells induced cytopathic effect to an
136 equivalent extent as those released in the culture supernatants (**Figure 1 – figure supplement**

137 **1B)**. Furthermore, we isolated annexin V-labeled apoptotic cells (AC) from SARS-CoV-2-
138 infected cell culture and confirmed that they carry viable viral particles **Figure 1G)**. Therefore,
139 viable SARS-CoV-2 is retained within infected, apoptotic epithelial cells.

140
141 Exposure of phosphatidylserine (PtdSer) on the outer plasma membrane of cells undergoing
142 regulated cell death (RCD), as observed by annexin V binding to infected dying cells (**Figure**
143 **1C)**, is the most ubiquitous signal that triggers their phagocytosis (Fadok et al., 1992; Nagata,
144 2018). To determine whether phagocytes efficiently engulf SARS-CoV-2-infected apoptotic cells
145 (CoV2-AC), we collected the loosely attached apoptotic cells from infected cultures and used
146 flow cytometry to assess their uptake by primary human macrophages and macrophages
147 differentiated from THP-1 monocytes. We observed that macrophages efficiently engulf CoV2-
148 AC, similarly to the uptake of sterile, UV-irradiated apoptotic cells (UV-AC) (**Figure 1H** and
149 **Figure 1 – figure supplement 1C)**. Analysis by confocal microscopy and staining for Spike
150 protein confirmed the presence of SARS-CoV-2 in engulfed cell corpses (**Figure 1 – figure**
151 **supplement 1D)**. Finally, either stimulation with infected or sterile dying cells did not robustly
152 affect macrophages viability up to 24 h post-treatment (**Figure 1 – figure supplement 1E)**.

153
154 These results demonstrate that macrophages engulf cell corpses carrying viable particles of
155 SARS-CoV-2, offering a framework to investigate their effects on macrophage function.

156
157 **Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory**
158 **function**

159

160 We next addressed the effect of the engulfment of SARS-CoV-2-infected apoptotic cells in
161 macrophages. The uptake of sterile apoptotic cells often promotes macrophage functional
162 polarization toward an anti-inflammatory and tissue repair phenotype (Doran et al., 2020). We
163 first observed that stimulation of primary monocyte-derived macrophages with CoV2-AC, but
164 not infection with SARS-CoV-2, reduced the expression of genes associated with alternative
165 programming to tissue remodeling and secretion of immune-modulatory mediators such as
166 *CCL18*, *CD206* (also known as *MRC1*), *MMP9*, *PPARG* and *CD163* (**Figure. 2A**). Furthermore,
167 stimulation with UV-AC obtained from infected Vero cells increased both gene (**Figure 2A**) and
168 surface protein (**Figure 2B, Figure 2 – figure supplement 1A**) expression of the anti-
169 inflammatory marker CD206. However, upregulation of MRC1 at the gene or protein levels did
170 not occur in response to stimulation with CoV2-AC (**Figures 2A and B**). We obtained similar
171 results in THP-1-derived macrophages stimulated with CoV2-AC obtained from either Calu-3 or
172 Vero cells infected with SARS-CoV-2 (**Figure 2 – figure supplement 1B-D**). Stimulation with
173 the conditioned supernatants of infected dying cells (containing putative DAMP, cytokines
174 produced by epithelial cells, extracellular vesicles, and released virions) or direct infection with
175 SARS-CoV-2 did not induce *MRC1* transcription (**Figure 2A, Figure 2 – figure supplement**
176 **1B**) or surface expression (**Figure 2B, Figure 2 – figure supplement 1C and D**) in
177 macrophages. We also confirmed that modulation of CD206 expression occurred specifically in
178 the macrophages that engulfed apoptotic cells and was not due to paracrine signaling (**Figure 2C**
179 and **Figure 2 – figure supplement 1E**). To determine if viral viability was required to modulate
180 CD206 expression by infected apoptotic cells, isolated CoV2-AC were exposed to UV
181 irradiation for virus inactivation (**Figure 2 – figure supplement 1F**). Notably, macrophages
182 treated with epithelial AC containing inactivated SARS-CoV-2 exhibited increased CD206

183 surface expression, similar to that of UV-AC (**Figure 2D**). This finding suggests that viable
184 SARS-CoV-2 actively represses alternative programming carried in dying cells and is not
185 primarily enforced by the type of cell death caused by the infection. Efferocytosis of sterile UV-
186 AC in the presence of SARS-CoV-2 still induced higher expression of CD206 in macrophages
187 (**Figure 2E**). Therefore, the suppression of CD206 surface expression required delivery of viral
188 particles within cell corpses to macrophages.

189
190 Conversely, the uptake of CoV2-AC, but not UV-AC, significantly increased *IL6* expression in
191 monocyte- and THP-1-derived macrophages (**Figure 3A** and **Figure 3 – figure supplement 1A**,
192 respectively). The uptake of CoV2-AC also induced robust secretion of inflammatory IL-6 and
193 IL-1 β , in both primary (**Figure 3B**) and THP-1-derived macrophages (**Figure 3 – figure**
194 **supplement 1B** and **C**). We did not detect these cytokines in macrophages stimulated with the
195 cell-free conditioned supernatants (**Figure 3B** and **Figure 3 – figure supplement 1A-C**), and
196 therefore this effect was not due to immune mediators or viral particles released from infected
197 epithelial cells. Importantly, assessment of IL-6 secretion in macrophages stimulated with sorted
198 out populations of infected dying cells revealed that cytokine production occurred specifically in
199 response to apoptotic cells, but not permeabilized dead cells (**Figure 3C**). In agreement, CoV2-
200 AC obtained from epithelial cells infected in the presence of osmoprotectant glycine, which non-
201 specifically prevents the leak of cytosolic content by lytic permeabilization (Evavold et al., 2017;
202 Frank et al., 2000) still induced robust secretion of IL-6 by macrophages (**Figure 3 – figure**
203 **supplement 1D**).

204

205 Further, the induction of inflammatory cytokines by SARS-CoV-2-loaded corpses required the
206 presence of viable viral particles, as UV-treatment or paraformaldehyde-fixation of isolated
207 CoV2-AC abrogated IL-6 secretion (**Figure 3D**). Notably, we did not observe robust production
208 of IL-6 in response to dying epithelial cells infected with Coxsackievirus (**Figure 3 – figure**
209 **supplement 1E** and **Figure 3E**). This result suggests that augmented pro-inflammatory cytokine
210 production is not a universal response of macrophages to the uptake of cell corpses infected with
211 positive single-strand viruses.

212
213 To confirm the requirement of recognition and binding of CoV2-AC to promote inflammatory
214 skewing, we stimulated macrophages in the presence of annexin V to mask PtdSer exposed on
215 the surface of the apoptotic cells. In the absence of PtdSer ligation, macrophages did not secrete
216 IL-6 in response to CoV2-AC (**Figure 3F** and **Figure 3 – figure supplement 1F**). Stimulation of
217 macrophages in the presence of actin depolymerization inducer Cytochalasin D, which allows
218 corpse binding but not internalization, also attenuated IL-6 production (**Figure 3G**). Finally, we
219 tested the effect of antiviral drugs targeting viral RNA transcription (RdRP-mediated RNA
220 synthesis). We found that Remdesivir treatment of primary macrophages following stimulation
221 with CoV2-AC partially reduced IL-6 secretion, suggesting that viral sgRNA expression is
222 important to modulate the inflammatory response (**Figure 3H**).

223
224 Collectively, these findings support that sensing and engulfment of dying cells carrying viable
225 SARS-CoV-2 switch macrophage anti-inflammatory, resolutive programming in response to
226 efferocytosis toward an inflammatory phenotype. The exacerbated cytokine production observed

227 in response to the efferocytosis of infected cell corpses by macrophages may contribute to the
228 cytokine storm associated with COVID-19 hyperinflammatory syndrome.

229

230 **Efferocytosis of SARS-CoV-2-infected dying cells suppresses continual clearance of**
231 **apoptotic cells**

232

233 Several receptors mediate efferocytosis through recognition of PtdSer on the surface of a dying
234 cell, either by direct binding or through a bridging molecule (Boada-Romero et al., 2020;
235 Penberthy and Ravichandran, 2016). We found that engulfment of CoV2-AC by primary
236 macrophages reduced the transcription of such PtdSer receptors, including the scavenger
237 receptors *CD36* and *SRA1*, $\alpha V\beta 5$ integrin (*ITGB5*), and T cell immunoglobulin mucin receptor 4
238 (*TIM4*) and MER proto-oncogene tyrosine kinase (*MERTK*) (**Figure 4A**). In THP-1-
239 macrophages, we also observed reduced expression of *SRA1*, *ITGB5*, and *TIM4* receptors in
240 response to infection with SARS-CoV-2 (**Figure 4 – figure supplement 1A**). Phagocytes can
241 ingest multiple corpses in subsequent rounds of efferocytosis (Miyaniishi et al., 2007; Morioka et
242 al., 2018; Park et al., 2011; Yurdagul et al., 2020). Previous *in vivo* work showed that
243 macrophages must continually remove ACs to promote efficient repair of injury and prevent the
244 accumulation of secondarily necrotic cells (Wang et al., 2017; Yurdagul et al., 2020). To
245 determine if repression of efferocytic receptors affects additional uptake of dying cells, we
246 treated macrophages with CoV2-AC and subsequently fed them with apoptotic human Jurkat
247 cells (UV-Jurkat). We found that the engulfment of SARS-CoV-2-infected corpses suppressed
248 the efferocytosis of other apoptotic cells (**Figure 4B-E, Figure 4 – figure supplement 1B**). As
249 infection with SARS-CoV-2 reduced the expression of some efferocytic receptors in THP-1

250 macrophages (**Figure 4 – figure supplement 1A**), we also tested if it affected the uptake of
251 apoptotic cells. Comparatively, infection with SARS-CoV-2 reduced AC clearance to a lower
252 extent than prior uptake of CoV2-AC (**Figure 4 – figure supplement 1C**). Notably, treatment
253 with Remdesivir did not improve the subsequent uptake by macrophages stimulated with CoV2-
254 AC, arguing that viral RNA replication is not required for suppression of efferocytosis in
255 response to CoV2-AC (**Figure 4F**). This result also suggests that different mechanisms lead to
256 pro-inflammatory cytokine production and efferocytosis repression in response to the uptake of
257 infected corpses.

258

259 Thus, efferocytosis of SARS-CoV-2-infected dying cells affects the expression of efferocytic
260 receptors and impairs the continual removal of apoptotic cells by macrophages.

261

262 **Lung monocytes and macrophages of severe COVID-19 patients express reduced levels of** 263 **efferocytic receptors**

264

265 To gain insight into the contribution of dysfunctional efferocytosis in COVID-19 pathogenesis,
266 we assessed the expression of efferocytic receptors by immunofluorescence in lung tissues
267 obtained from autopsies of deceased COVID-19 patients. We found a reduction in the protein
268 levels of CD36 in S1009⁺ infiltrating phagocytes in the lungs of COVID-19 patients compared to
269 control tissues (**Figure 5A**). Phagocytes in the lungs of COVID-19 patients also expressed lower
270 protein levels of MERTK (**Figure 5B**).

271

272 Using publicly available single-cell RNA sequencing (scRNA-seq) data from bronchoalveolar
273 lavage (BAL) (Liao et al., 2020), we performed enrichment analysis using the genes
274 differentially expressed (DEG) in mild and severe COVID-19 patients compared with healthy
275 individuals. We targeted efferocytosis-related gene ontology (GO) annotated pathways and
276 customized gene sets based on the literature (Boada-Romero et al., 2020; Penberthy and
277 Ravichandran, 2016) (**Supplementary File 1**). Independent analysis of clusters previously
278 assigned as macrophages (Liao et al., 2020) revealed significant repression of gene sets related to
279 efferocytosis in severe patients (**Figure 5C**). While differences were evident between moderate
280 and severe patients were observed in clusters expressing markers of early infiltrating phagocytes
281 (S1009⁺ CCL18⁻), they were more pronounced in mature, likely anti-inflammatory macrophages
282 (S11009⁻ CCL18⁺). Notably, reassessment on scRNAseq by Ren et al. (2021) showed
283 enrichment in pathways related to efferocytosis for genes repressed in alveolar macrophages
284 which were positive for SARS-CoV-2 RNA compared with those which were negative to the
285 virus (**Figure 5D**). This finding is consistent with the notion that uptake of infected cells reduces
286 the capacity of macrophages to clear other dead cells. Altogether, these data support that
287 macrophages in the lungs of severe COVID-19 patients may also fail in their efferocytic
288 capacity.

289

290 **Discussion**

291

292 Patients with severe COVID-19 develop life-threatening inflammatory process in the lungs with
293 underlying causes still not established. Here, we demonstrate that the sensing and engulfment of
294 SARS-CoV-2-infected dying cells by macrophages switches the effector response to

295 efferocytosis from a potential wound healing, anti-inflammatory function to a pro-inflammatory
296 one. Our data supports that the uptake of cell corpses infected with SARS-CoV-2 exacerbates the
297 secretion of inflammatory IL-6 and IL-1 β , suggesting a mechanism for the robust secretion of
298 cytokines related to COVID-19 cytokine storm. Another important consequence of this shift in
299 macrophage function is the impairment of macrophage capacity to engulf apoptotic cells
300 continually and promote proper injury resolution. Instead, our data suggest that efferocytosis of
301 infected cells may augment tissue damage by causing inefficient clearance of dead cells. This
302 process may consequently contribute to respiratory complications developed by patients with the
303 severe form of the disease and increase susceptibility to secondary bacterial infections for the
304 lack of effective disease tolerance mechanisms that restrain collateral tissue damage (Jamieson et
305 al., 2013). While such causal connection remains to be investigated, our histological assessment
306 and reanalysis of scRNAseq datasets suggest that the efferocytic capacity of lung macrophages is
307 impaired in the lungs of COVID-19 patients.

308
309 In the context of COVID-19 immunopathogenesis, excessive amounts of necrotic cells may lead
310 to high levels of circulating DAMP, such as HMGB1 and lactate dehydrogenase (LDH), both of
311 which correlate with disease severity (Chen et al., 2020; Han et al., 2020; Rodrigues et al., 2020).
312 It is thus possible that the combination of exacerbated cytokine production and interruption of
313 continual efferocytosis in response to engulfment of SARS-CoV-2-infected corpses could both
314 increase the magnitude and duration of inflammation, contributing to the hyperinflammatory
315 state and multiorgan damage in COVID-19. Finally, some studies reported higher levels of
316 autoantibodies (such as against IFN γ , phospholipids, and annexin A2) in COVID-19 patients
317 (Bastard et al., 2020; Zuniga et al., 2021; Zuo et al., 2020), suggesting that autoantibodies may

318 drive the worsening of the disease. It has long been known that defective engulfment or
319 processing of dying cells causes the development of autoimmune diseases (Boada-Romero et al.,
320 2020; Cohen et al., 2002; Miyanishi et al., 2007; Peng and Elkon, 2011; Rodriguez-Manzanet et
321 al., 2010). In light of our findings, perhaps defective clearance of apoptotic cells caused by
322 SARS-CoV-2 infection and SARS-CoV-2-loaded ACs also contributes to COVID-19-associated
323 autoimmunity.

324
325 As it becomes clear that worsening of COVID-19 occurs because of immune dysfunction,
326 antivirals, and other therapeutic efforts to limit viral replication may fail to benefit critically ill
327 patients. In those patients, successful therapeutic strategies may rely on targeting dysregulated
328 components of the host response to limit damage to the host, thus promoting disease tolerance
329 and stimulating a resolute response that restores homeostasis. In this context, our study
330 provides important insights into the mechanisms driving the pathophysiology of COVID-19 that
331 can be explored in the design of therapeutics approaches toward harnessing innate immune
332 responses and macrophage function during the evolution of SARS-CoV-2 infection.

333

334 **Material and Methods**

335 **Study approval.** The procedures followed in the study were approved by the Research Ethics
336 Committee of Hospital das Clínicas de Ribeirão Preto (CEP-FMRP/USP) and by the National
337 Ethics Committee, Brazil (Comissão Nacional de Ética em Pesquisa (CONEP), protocols
338 30248420.9.0000.5440 and 39722020.9.0000.5440. Written informed consent was obtained from
339 recruited donors.

340

341 **Isolation of human peripheral blood mononuclear cells, monocyte seeding, and**
342 **macrophage differentiation.** Peripheral blood mononuclear cells (PBMC) from healthy donors
343 were isolated from peripheral blood. The samples were centrifuged at 400 g for 10 min at room
344 temperature (RT), the plasma was discarded, and the cellular portion was diluted in phosphate-
345 buffered saline (PBS). PBMC were isolated by density–gradient centrifugation using
346 Histopaque-1077 (Sigma-Aldrich). The collected PBMC fraction was treated with ACK lysis
347 buffer to lyse erythrocytes and washed twice with PBS. For macrophages differentiation,
348 monocytes were cultivated for 7 d in RPMI 1640 media supplemented with penicillin (10.000
349 U/mL, GIBCO), streptomycin (10.000 µg/mL, GIBCO), 1% glutamine (GIBCO), and 10% heat-
350 inactivated human serum (Sigma Aldrich) at 37°C in a 5% CO₂ atmosphere.

351
352 **Cell Lines.** Calu-3 and Jurkat cells were originally from (ATCC®) and purchased from Banco de
353 Células do Rio de Janeiro (BCRJ). Vero CCL81 and THP-1 cells were from Dario Zamboni's
354 lab. No authentication method was used. Calu-3 and Vero CCL81 cells were maintained in
355 DMEM with 4.5 g/L glucose (GIBCO) supplemented with penicillin (10,000 U/mL),
356 streptomycin (10,000 µg/mL), and 10% heat-inactivated fetal bovine serum (FBS, GIBCO)
357 (DMEMc) at 37°C in a 5% CO₂ atmosphere. Jurkat cells and THP-1 cells were maintained in
358 RPMI1640 media supplemented with penicillin (10,000 U/mL), streptomycin (10,000 µg/mL),
359 1% glutamine, and 10% FBS (RPMIc) at 37°C in a 5% CO₂ atmosphere.

360
361 THP-1-derived macrophages were obtained by treatment with phorbol 12-myristate 13-acetate
362 (PMA, 50 ng/mL, Sigma-Aldrich) for 24 h, followed by media replenishment with fresh RPMIc
363 and other 24 h incubation period before stimulation.

364

365 Cell lines were routinely screened by PCR for mycoplasma contamination, and all cell lines
366 tested negative.

367

368 **Viral stock.** The SARS-CoV-2 strain (Brazil/SPBR-02/2020) was isolated from the first
369 Brazilian case of COVID-19. The viral stock was produced in a monolayer of Vero CCL81 cells
370 expressing ACE2 (Rodrigues et al., 2020), maintained in serum-free DMEM at 37°C in a 5%
371 CO₂ atmosphere. Coxsackievirus B5 (Coxsackie) was originally shared by Dr. Roger M. Loria
372 (Virginia Commonwealth University, Richmond, Virginia, USA) (Gomes et al., 2009). The viral
373 stock was produced in a monolayer of HeLa cells maintained in DMEM supplemented with 2%
374 FBS at 37°C and 5% CO₂. Viral stocks were propagated under BSL3 conditions and stored at -
375 80°C. Viral loads were estimated by titration in Vero CCL81 cells seeded onto 96-well plates
376 and standard limiting dilution to confirm the 50% tissue culture infectious dose.

377

378 **Infection and UV-irradiation of epithelial cell lines.** Cell monolayers were rinsed with PBS,
379 replenished with a thin layer of serum-free media, and infection with a freshly thawed virus
380 aliquot at a multiplicity of infection (MOI) of approximately 0.05 was carried out for 1 h at 37°C
381 and 5% CO₂ for viral adsorption. The cells were then topped with fresh media and incubated for
382 48 h. Sterile apoptotic cells (UV-AC) were generated by exposure to UV-C radiation (Calu-3
383 cells at 500 mJ/cm² and Vero CCL81 cells at 350 mJ/cm²) in a UV crosslinker (Fisher
384 Scientific), followed by 6h incubation in DMEMc at 37°C and 5% CO₂.

385

386 **Cell death assays.** Cells were collected 48 hours post-infection or 6 hours post-irradiation, spun
387 at 300 g for 5 min, washed with PBS, and resuspended in the appropriate buffer before analysis.

388
389 For the analysis of caspase-8 and caspase-3 cleavage, 2.0×10^6 Vero CCL81 and Calu-3 cells
390 stimulated as described were lysed in RIPA buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150
391 mM NaCl, 1% Nonidet P-40, 1% deoxycholate, and 0.1% SDS) supplemented with protease
392 inhibitor cocktail (Sigma). Precleared lysates were quantified by Bradford assay, boiled in
393 Laemmli buffer, resolved by SDS-PAGE and transferred to PVDF membranes. Rabbit anti-
394 cleaved caspase-3/caspase-3/cleaved Caspase-8/caspase-8 (all from Cell Signaling), rabbit anti-
395 SARS-CoV-2 Spike (Abcam), HRP-conjugated goat anti-actin (Cell Signaling), and species-
396 specific horseradish-conjugated secondary antibodies were used for antigen detection.

397
398 For the analysis of cleaved caspase-3 by flow cytometry, infection of Calu-3 cells was carried
399 out in the presence of Z-VAD-FMK (Selleckchem) at 20 μ M, or mock treatment with vehicle
400 (DMSO), added to cell cultures after virus adsorption. 10^6 collected cells were washed with PBS,
401 and fixation, permeabilization, and staining were carried out using BD Cytotfix/Cytoperm™
402 Fixation/Permeabilization Kit (BD Biosciences), following the manufacturer's instructions.
403 Samples were incubated with rat serum (1:400) for 5 min at RT followed by immunolabelling of
404 intracellular active caspase-3 was performed with anti-cleaved caspase-3 (Cell Signaling, 1:400)
405 and secondary donkey anti-rabbit IgG conjugated to Alexa Fluor 488 (Thermo Fisher Scientific,
406 1:2,500). Sample acquisitions were performed in a FACSVerse™ (BD Biosciences) flow
407 cytometer and data processing was performed using FlowJo_V10 software (BD Biosciences).

408

409 Cell death profiling in infected or UV-irradiated Vero CCL81 cells was performed with a
410 viability dye (Zombie NIR™ Fixable Viability Dye, Biolegend, 1:400) and annexin V (FITC
411 annexin V, BD Biosciences, 1:200) co-labeling. Labeling of 1.0×10^6 cells with Zombie NIR
412 was carried out for 10 min on ice, followed by annexin V labeling for 15 min on ice with cells
413 resuspended in annexin V binding buffer (0.01M HEPES, 0.14M NaCl, 2.5 mM CaCl₂, pH 7.4).
414 Sample acquisitions were performed in a BD FACSMelody™ (BD Biosciences) cell sorter
415 and data processing was performed using FlowJo_V10 software (BD Biosciences).

416

417 To determine LDH release, infection or UV-irradiation of 2.0×10^5 Vero CCL18 cells were
418 carried out in DMEMc without Phenol Red. LDH release was measured in the culture
419 supernatants using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega), following
420 the manufacturer's instructions.

421

422 **Isolation of apoptotic cells.** Apoptotic cells were generated from SARS-CoV-2-infected (CoV2-
423 AC) or UV-irradiated (UV-AC) Vero CCL81 and Calu-3 cells, or Coxsackievirus B5-infected
424 Vero CCL81 cells (Coxsackie-AC). At the established time points, the supernatants were
425 collected and temporarily stored for further processing. Then, a suspension containing CoV2-
426 AC, Coxsackie-AC or UV-AC was obtained by carefully pipetting fresh media up and down the
427 plate surface and collecting loosely attached cells. Following spun at 300 g for 5 min, pelleted
428 AC were washed with PBS, resuspended in RPMIc, and counted prior to incubation with
429 macrophages. Enrichment in apoptotic cells were confirmed by annexin V staining and flow
430 cytometry.

431

432 To sort CoV2-AC populations, annexin V⁺ cells were pre-enriched using magnetic separation
433 (Annexin V MicroBead Kit, Miltenyi Biotec) following the manufacturer's instructions. Then
434 cells were labeled with Zombie NIR and annexin V-FITC, as described above, and cell sorting
435 were performed in a BD FACSMelody™ (BD Biosciences) cell sorter. Isolated CoV2-AC were
436 washed in PBS, resuspended in fresh RPMIc, and counted prior to incubation with macrophages
437

438 For virus inactivation, isolated CoV2-AC suspension was placed onto tissue culture hood surface
439 with an open lid for 20 min with the UV-C lamp on. Virus inactivation was confirmed by
440 TCID₅₀, as described below. Alternatively, isolated AC were fixed with 2% paraformaldehyde
441 (PFA) in PBS for 10 min and washed twice with PBS before adding to macrophage cultures.

442
443 To prepare the cell-free conditioned supernatants of the infected AC (CoV2-AC Sup), collected
444 supernatants were spun at 300 g for 5 min to remove cellular debris; the resulting supernatant
445 was filtered using a 0.22 µm syringe filter and immediately used for macrophage stimulation.
446 The volume of CoV2-AC Sup used to stimulate macrophages was normalized to the amount of
447 collected AC.

448
449 **TCID₅₀ quantification of viable viral particles.** 1.0 x 10⁶ isolated CoV2-AC and their
450 equivalent purified conditioned supernatants, obtained as described above, were lysed by snap
451 freeze-and-thaw. To estimate viral load in apoptotic cells isolated by annexin V labeling, all
452 infected cells were collected, followed by magnetic separation with annexin V MicroBeads
453 (Miltenyi Biotec) according to the manufacturer's protocol. 1.0 x 10⁶ pre-sorted cells and
454 annexin⁺ cells were lysed by freeze-and-thaw for quantification. Viral loads were estimated by

455 titration in Vero CCL81 cells seeded onto 96-well plates and expressed as 50% tissue culture
456 infectious dose (TCID₅₀). Quantification was performed with the Reed-Muench method and
457 plotted as TCID₅₀ units per mL (Reed and Muench, 1938).

458
459 ***In vitro* assays with THP-1- and PBMC-derived macrophages.** 1.0 x 10⁶ THP-1- and PBMC-
460 derived macrophages seeded on 24-well tissue culture plates were rinsed with warm PBS before
461 stimulation. Macrophage cultures were then topped with UV-AC, CoV2-AC, or Coxsackie-AC
462 resuspended in the appropriate serum-containing macrophage media at a 1:1 ratio. Macrophage
463 cultures were rinsed out 2 h after incubation to remove unbound AC and topped with fresh media
464 at the indicated time points, cell supernatants were collected and macrophages were rinsed at
465 least twice with warm PBS to remove cell debris before proceeding to further analysis. To block
466 AC ligation and efferocytosis, CoV2-AC were pre-incubated with 0.1 or 0.01 µg/mL of annexin-
467 V (BD Biosciences) and macrophage stimulation was carried out in RPMIc supplemented with
468 Ca²⁺. To block AC internalization, macrophages were pre-treated for 30 min, and incubation was
469 carried out in the presence of Cytochalasin D (10 µM, Sigma). Where indicated, macrophages
470 were topped with fresh media containing Remdesivir (20 µM, BOC Sciences) after removal of
471 unbound AC.

472
473 For stimulation with conditioned supernatants, CoV2-AC-Sup were added directly to
474 macrophages cultures and topped with fresh media for volume adjustment. Infection with SARS-
475 CoV-2 or Coxsackie virus was carried out with virus adsorption at MOI 0.1 in serum-free media
476 for 1 h before topping with fresh serum-containing media.

477

478 For gene expression analysis by RT-qPCR, rinsed macrophage cultures were lysed in Trizol
479 (Thermo Scientific) and immediately frozen at -80°C.

480

481 To estimate CD206 surface expression, rinsed macrophages were removed with a cell scraper,
482 spun at 300 g for 5 min, washed with PBS, followed by incubation with rat serum (1:400) for 5
483 min at RT and cell surface staining for 15 minutes at 4°C. Cells were labeled with Zombie
484 Violet™ Fixable Viability Kit (Biolegend) and anti-CD206-FITC antibody (clone 19.2, BD
485 Biosciences). The cells were then fixed with 2% PFA for 10 min and washed before flow
486 cytometric analyses in a FACSVerse (BD Biosciences) flow cytometer and data processing was
487 performed using FlowJo_V10 software (BD Biosciences).

488

489 For immunofluorescence imaging of efferocytosis in vitro, human monocyte-derived
490 macrophages seeded onto 13mm round coverslips were incubated with UV-AC or CoV2-AC
491 labeled with 5 µM CellTrace™ CFSE dye (Thermo Scientific) for 2 h. After rinsing out non-
492 engulfed AC, macrophages were fixed for 20 min with PBS 2% PFA at RT. Cells were then
493 permeabilized with 0.1% Triton-X-100 in PBS for 10 min at room temperature RT. Next, cells
494 were rinsed twice in PBS and incubated with PBS 1% bovine serum albumin (BSA) and 5
495 µg/mL normal donkey IgG (Jackson ImmunoResearch) for 45 min RT prior to overnight (ON)
496 incubation at 4°C with primary antibodies: rabbit polyclonal anti-SARS-CoV-2 Spike antibody
497 (Abcam, 1:1,000) and mouse mAb anti-rat CD11b (Abcam, 1:300) diluted in PBS containing 1%
498 BSA. Next, cells were rinsed thoroughly in PBS and incubated for 30 min at RT with the
499 secondary antibodies diluted in PBS: Alexa-594 goat-anti rabbit IgG (1:1,000; Thermo
500 Scientific) and Alexa-647 donkey-anti mouse IgG (1:1,000; Thermo Scientific). Cell nuclei were

501 stained with Hoechst 33342. Cells were then rinsed, and coverslips mounted on glass slides with
502 Fluoromount-G (Invitrogen). Samples were imaged using a Zeiss LSM 780 laser scanning
503 confocal microscope (Carl Zeiss), postprocessed for brightness and contrast adjustment with
504 ImageJ image processing package (NIH) and layouts were built on Adobe Photoshop.
505
506 For the engulfment assays by flow cytometry, macrophages were labeled with 5 μ M CellTrace™
507 Violet dye (CTV, Thermo Scientific), according to the manufacturer's recommendations.
508 CellTrace™ Violet (CTV)-labeled macrophages were stimulated with UV-AC or CoV2-AC
509 previously stained with 1 μ M CellTrace™ Far Red dye (CTFR, Thermo Scientific), or 5 μ M
510 CellTrace™ CFSE dye, as described in the legend of the figures. Following the removal of
511 unbound AC, macrophages were collected with a cell scraper, fixed with 2% PFA for 10 min,
512 and washed before proceeding with the acquisition by flow cytometry. For the two-round
513 efferocytosis assay, first-round UV-AC and CoV2-AC were labeled with a pH indicator
514 fluorogenic intracellular probe (pHRodo Red AM Intracellular pH Indicator - Thermo
515 Scientific). Second-round apoptotic Jurkat cells (UV-Jurkat) were generated by labeling with 1
516 μ M CTFR and UV-C irradiation at 20 mJ/cm², followed by incubation at 37°C and 5% CO₂ for 6
517 h. CTV-labeled THP-1 cells were incubated with pHRodo-UV-AC or pHRodo-CoV2-AC for 18h
518 at a 1:1 ratio. Cells were then rinsed with PBS, and CTV-labeled UV-Jurkat were added to the
519 culture at a 1:1 ratio for 2h. Macrophage cultures were collected with a cell scraper, washed,
520 fixed with 2% PFA for 10 min, and washed before proceeding with the acquisition by flow
521 cytometry. Flow cytometric acquisition was performed in a FACSVerse (BD Biosciences) flow
522 cytometer and data processing was performed using FlowJo_V10 software (BD Biosciences).
523

524 **Cytokine quantification.** IL-6 and IL-1 β cytokine levels in macrophage supernatants were
525 evaluated by ELISA assay (R&D Systems) or Cytometric Bead Array (CBA, BD Biosciences),
526 as indicated in the legend of the figures, following the manufacturers' recommendations.

527

528 **RNA isolation and gene expression analyses.** Total RNA extraction for human monocyte- or
529 THP-1-derived macrophages stimulated *in vitro* was performed using DirectzolTM RNA
530 miniPrep Kit (Zymo Research), following the manufacturer's recommendations. Reverse
531 transcriptase was performed using M-MLV reverse transcriptase (Thermo Scientific) according
532 to the manufacturer's recommendations.

533

534 Gene expression RT-qPCR was performed using SybrGreen Master Mix (Applied Biosystems).
535 RT-qPCR was performed in fast mode, following the manufacturer's recommendations. The
536 evaluation of each gene expression was determined by the comparative CT method. Primer
537 sequences used were:

538

Gene	5' Forward	3' Reverse
CCL18	CTCTGCTGCCTCGTCTATACCT	CTTGGTTAGGAGGATGACACCT
CD163	GCGGGAGAGTGGAAGTGAAAG	GTTACAAATCACAGAGACCGCT
CD36	GGGAAAGTCACTGCGACATG	TGCAATACCTGGCTTTTCTCA
GAPDH	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA
IL6	GGTACATCCTCGACGGCATCT	GTGCCTCTTTGCTGCTTTCAC
ITGB5	AACCAGAGCGTGTACCAGAA	AGGAGAAGTTGTTCGCACTCA
MERTK	CTCTGGCGTAGAGCTATCACT	AGGCTGGGTGTTGGTGAACA
MMP9	TGTACCGCTATGGTTACACTCG	GGCAGGGACAGTTGCTTCT
MRC1	AGCCAACACCAGCTCCTCAAGA	CAAAACGCTCGCGCATTGTCCA
PPARG	ACCAAAGTGCAATCAAAGTGGA	ATGAGGGAGTTGGAAGGCTCT
SRA1	GCAGTGGGATCACTTTCACAA	AGCTGTCATTGAGCGAGCATC
TIM4	ACAGGACAGATGGATGGAATA CCC	AGCCTTGTGTGTTTCTGCG

539

540 **Histological analysis.** Ultrasound-guided minimally invasive autopsies for COVID-19 deceased
541 patients were approved by the Research Ethics Committee of Hospital das Clínicas de Ribeirão
542 Preto (CEP, protocol no. 4.089.567). **Supplementary File 2** describes clinical, laboratory, and
543 treatment records of COVID-19 patients. Non-neoplastic sections of lung parenchyma were
544 obtained from lobectomies for lung cancer as a control group (Rodrigues et al., 2020). Paraffin
545 sections from lungs were collected and processed as previously described (Rodrigues et al.,
546 2020). Sections were rinsed in PBS, and the antigen retrieval was performed by incubation of
547 samples with 0.1% trypsin (ThermoFisher Scientific) in PBS at 37°C for 15 min. Next, sections
548 were rinsed and incubated with Image-iT FX Signal Enhancer (ThermoFisher Scientific) for 30
549 min at RT. Sections were then rinsed in PBS and incubated for 45 min at RT in PBS containing
550 0.5% BSA and 5µg/mL normal donkey IgG (Jackson ImmunoResearch).

551
552 For analysis of active caspase-3, lung sections were labeled with primary antibodies diluted in
553 PBS and incubated overnight at 4°C: rabbit polyclonal anti-human cleaved caspase-3 (Asp175)
554 (Cell Signaling; 1:1,000) and mouse anti-dsRNA (SCICONS; 1:1,000). Then, sections were
555 rinsed thoroughly in PBS and incubated for 45 min at RT with the secondary antibodies: Alexa
556 594 goat anti-rabbit IgG (1:500; Thermo Fisher Scientific) and Alexa 488 goat anti-mouse IgG
557 F(ab)₂ (1:500; Thermo Fisher Scientific) diluted in PBS. Cell nuclei were stained with Hoechst
558 33342. Cells were then rinsed, and coverslips mounted on glass slides with Fluoromount-G
559 (Invitrogen). For *in situ* efferocytosis analysis, lung sections were labeled with primary
560 antibodies mouse mAb anti-human CD68 (Abcam; 1:100), rabbit mAb anti-human cytokeratin
561 18 (GeneTex, 1:500) diluted in PBS and incubated overnight at 4°C. Then, sections were rinsed
562 thoroughly in PBS and incubated for 45 min at RT with the secondary antibodies F(ab)₂ goat

563 anti-mouse IgG conjugated to Alexa 488 (1:500; Thermo Scientific) and goat anti-rabbit IgG
564 conjugated to Alexa 647 (1:500; Thermo Scientific). Next, sections were rinsed in PBS and
565 incubated overnight at 4°C with rabbit polyclonal anti-SARS-CoV-2 Spike (Abcam; 1:1,000)
566 previously conjugated to Alexa 568, according to the manufacturer's instructions (Zenon Alexa
567 Fluor 568 Rabbit IgG Labeling Kit, Thermo Scientific). Sections were then rinsed in PBS and
568 incubated for 15 min at RT with Hoechst 33342 (Invitrogen), rinsed thoroughly, and mounted on
569 glass slides with Fluoromount-G (Invitrogen). Samples from Cl-caspase-3 and in situ
570 efferocytosis experiments were imaged using an ECLIPSE Ti2 Series microscope equipped with
571 a DS-Qi2 camera (Nikon Instruments Inc.). Analysis was performed using NIS Elements (Nikon
572 Instruments Inc.), wherein mean intensity fluorescence for Cl-caspase-3 was determined for
573 randomly selected epithelial cells. Representative images were postprocessed for brightness and
574 contrast adjustment with ImageJ image processing package (NIH) and layouts were built on
575 Adobe Photoshop.

576
577 For CD36 or MERTK expression analysis, lung sections were labeled with the primary
578 antibodies diluted in PBS and incubated overnight at 4°C: rabbit polyclonal anti-human CD36
579 (PA5-81996; 1:100 ThermoFisher Scientific) or rabbit mAb anti-human MERTK (Clone SR29-
580 07; 1:150; ThermoFisher Scientific) and mouse mAb anti-human calprotectin (Clone MAC387;
581 MA1-81381; 1:100; ThermoFisher Scientific). Then, sections were rinsed thoroughly in PBS and
582 incubated for 45 min at RT with the secondary antibodies Alexa 488 donkey anti-rabbit IgG
583 (1:500; Thermo Fisher Scientific) and Alexa 594 goat anti-mouse IgG (Thermo Scientific)
584 diluted in PBS. Sections were then rinsed, and coverslips mounted with DAPI Fluoromount-G.
585 Samples were imaged using an Olympus BX61 Fluorescence Motorized Slide Scanner

586 Microscope Pred VS120 (Olympus). Analysis was performed using ImageJ image processing
587 package (NIH), wherein mean intensity fluorescence for CD36 and MERTK was determined for
588 randomly selected S1009⁺ cells. Representative images were postprocessed for brightness and
589 contrast adjustment with ImageJ image processing package (NIH) and layouts were built on
590 Adobe Photoshop.

591

592 **Re-analysis of scRNA-seq Data.** We re-analyzed single-cell transcriptomic data from
593 bronchoalveolar lavage fluid (BAL) from patients with varying severity of COVID-19 disease
594 and their respective healthy controls (Liao et al., 2020). The dataset is publicly available at
595 <https://covid19-balf.cells.ucsc.edu/>. Downloaded data was imported into R environment version
596 v3.6.3. Differential expression analysis was conducted using FindMarkers function in Seurat
597 using the Wilcoxon test to compare mild and severe COVID-19 patients with healthy individuals
598 for each cluster previously identified by authors. Differentially expressed genes between
599 mild/severe COVID-19 patients and controls for each cluster were identified considering genes
600 expressed in at least 5% of cells and $FDR < 0.05$ and $|\text{avg_logFC}| > 0.1$. In addition, a
601 differentially expressed gene list comparing infected (identified SARS-Cov-2 transcripts) against
602 non-infected alveolar macrophages were obtained from supplemental materials from (Ren et al.,
603 2021). Gene Set Enrichment Analysis (GSEA) was performed using ClusterProfiler and fgsea R
604 packages (Korotkevich et al., 2021; Wu et al., 2021) for each differentially expressed gene or
605 log₂ fold-change lists from Liao et al. (2020) and Ren et al. (2021) dataset. A custom gene set
606 was also utilized as a reference for GSEA, incorporating GO:0006911, GO:0043277 gene
607 ontology terms, and additional efferocytic related genes from the literature (Penberthy and

608 Ravichandran, 2016; Boada-Romero et al., 2020) (**Table S1**). Significantly enriched sets were
609 identified considering terms with p-value < 0.05.

610

611 **Quantification and statistical analyses.** Please refer to the legend of the figures for description
612 of samples, sample sizes (biological replicates) and experimental replicates. No statistical tests
613 were used to estimate sample size. Data were plotted and analyzed with GraphPad Prism 8.4.2
614 software (GraphPad Prism Software Inc., San Diego, CA). The statistical tests used are listed in
615 the legend of the figures. For the *in vitro* assays, we used Student's t-test to compare two
616 experimental groups or ANOVA and multiple comparison correction, to compare three or more
617 experimental groups. For quantification of histological datasets, normality tests were performed,
618 and samples with non-Gaussian distribution were analyzed applying the Mann–Whitney test.

619

620 **Acknowledgements**

621 The authors thank Dr. Denise M. da Fonseca, Msc. Elizabete R. Milani and Dr. Roberta
622 R. C. Rosales (FMRP-USP) for technical assistance.

623

624 **Funding:** This work was supported by grants from:

625 Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) grants
626 2018/25559-4 and 2020/05288-6 (L.D.C)

627 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) grant
628 88887.507253/2020-00 (D. S. Z. and L.D.C.)

629 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grant
630 434538/2018-3 (L.D.C.)

631 D. S., A. C. G. S., T. S. R., M. F. R., E. G. F. F., D. L. A. T. are supported by
632 FAPESP fellowships.

633

634 **Competing Interests**

635 The authors declare no competing financial interests.

636

637 **Data Availability**

638 All data are available in the main text or supporting information.

639

640 **References**

641

- 642 A-Gonzalez N, Quintana JA, García-Silva S, Mazariegos M, Aleja AG de la, Nicolás-Ávila JAA,
643 Walter W, Adrover JM, Crainiciuc G, Kuchroo VK, Rothlin CV, Peinado H, Castrillo A,
644 Ricote M, Hidalgo A. 2017. Phagocytosis imprints heterogeneity in tissue-resident
645 macrophages. *The Journal of experimental medicine* 214:1281–1296.
646 doi:10.1084/jem.20161375
- 647 Banerjee S, Friggeri A, Liu G, Abraham E. 2010. The C-terminal acidic tail is responsible for the
648 inhibitory effects of HMGB1 on efferocytosis. *J Leukocyte Biol* 88:973–979.
649 doi:10.1189/jlb.0510262
- 650 Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, Dorgham K, Philippot
651 Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L,
652 Trouillet-Assant S, Dobbs K, Jesus AA de, Belot A, Kallaste A, Catherinot E, Tandjaoui-
653 Lambiotte Y, Pen JL, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN,
654 Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar
655 K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-
656 Murci L, Beek D van de, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-
657 Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G,
658 Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen J, Biondi A, Bettini LR, D’Angio M,
659 Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV,
660 Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari
661 A, Marseglia GL, Duval X, Ghosn J, Lab§ H, Group§ N-UIR to C, Clinicians§ C, Clinicians§
662 C-S, Group§ IC, Group§ FCCS, Consortium§ TMI, Cohort§ C-C, Biobank§ AUC-19, Effort§
663 CHG, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang S-Y, Holland
664 SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC,

- 665 Casanova J-L. 2020. Auto-antibodies against type I IFNs in patients with life-threatening
666 COVID-19. *Science* eabd4585. doi:10.1126/science.abd4585
- 667 Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi
668 K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. 2020.
669 Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*
670 181:1036-1045.e9. doi:10.1016/j.cell.2020.04.026
- 671 Boada-Romero E, Martinez J, Heckmann B, Green D. 2020. The clearance of dead cells by
672 efferocytosis. *Nat Rev Mol Cell Bio* 1–17. doi:10.1038/s41580-020-0232-1
- 673 Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, Weinstein JS, Licona-
674 Limon P, Schmid ET, Pelorosso F, Gagliani N, Craft JE, Flavell RA, Ghosh S, Rothlin CV.
675 2017. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with
676 apoptotic cells. *Sci New York N Y* 356:1072–1076. doi:10.1126/science.aai8132
- 677 Chan JF-W, Zhang AJ, Yuan S, Poon VK-M, Chan CC-S, Lee AC-Y, Chan W-M, Fan Z, Tsoi
678 H-W, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai J-P, Kok K-H, Chu H, Chan K-H,
679 Sridhar S, Chen Z, Chen H, To KK-W, Yuen K-Y. 2020. Simulation of the Clinical and
680 Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian
681 Hamster Model: Implications for Disease Pathogenesis and Transmissibility. *Clin Infect Dis*
682 *Official Publ Infect Dis Soc Am* 71:2428–2446. doi:10.1093/cid/ciaa325
- 683 Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, Wei J, Luo H, Zhu H, Huang Liang, Meng F,
684 Huang Lifang, Wang N, Zhou X, Zhao L, Chen X, Mao Z, Chen C, Li Z, Sun Z, Zhao J,
685 Wang D, Huang G, Wang W, Zhou J. 2020. Elevated serum levels of S100A8/A9 and
686 HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19
687 patients. *Cell Mol Immunol* 17:992–994. doi:10.1038/s41423-020-0492-x
- 688 Chu H, Chan JF-W, Yuen TT-T, Shuai H, Yuan S, Wang Y, Hu B, Yip CC-Y, Tsang JO-L,
689 Huang X, Chai Y, Yang D, Hou Y, Chik KK-H, Zhang X, Fung AY-F, Tsoi H-W, Cai J-P,
690 Chan W-M, Ip JD, Chu AW-H, Zhou J, Lung DC, Kok K-H, To KK-W, Tsang OT-Y, Chan
691 K-H, Yuen K-Y. 2020. Comparative tropism, replication kinetics, and cell damage profiling
692 of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations,
693 transmissibility, and laboratory studies of COVID-19: an observational study. *Lancet Microbe*
694 1:e14–e23. doi:10.1016/s2666-5247(20)30004-5
- 695 Chu H, Shuai H, Hou Y, Zhang X, Wen L, Huang X, Hu B, Yang D, Wang Y, Yoon C, Wong
696 BH-Y, Li C, Zhao X, Poon VK-M, Cai J-P, Wong KK-Y, Yeung M-L, Zhou J, Au-Yeung
697 RK-H, Yuan S, Jin D-Y, Kok K-H, Perlman S, Chan JF-W, Yuen K-Y. 2021. Targeting
698 highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease
699 severity. *Sci Adv* 7:eabf8577. doi:10.1126/sciadv.abf8577
- 700 Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
701 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, Veer B van der, Brink S van den,
702 Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
703 Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-
704 time RT-PCR. *Eurosurveillance* 25:2000045. doi:10.2807/1560-7917.es.2020.25.3.2000045
- 705 Doran AC, Yurdagul A, Tabas I. 2020. Efferocytosis in health and disease. *Nat Rev Immunol*
706 20:254–267. doi:10.1038/s41577-019-0240-6
- 707 Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC. 2017. The Pore-Forming Protein
708 Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. *Immunity* 48:35-
709 44.e6. doi:10.1016/j.immuni.2017.11.013

- 710 Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. 1992. Exposure of
711 phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and
712 removal by macrophages. *J Immunol Baltim Md 1950* 148:2207–16.
- 713 Feng X, Deng T, Zhang Y, Su S, Wei C, Han D. 2011. Lipopolysaccharide inhibits macrophage
714 phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α
715 and growth arrest-specific gene 6. *Immunology* 132:287–295. doi:10.1111/j.1365-
716 2567.2010.03364.x
- 717 Frank A, Rauen U, Groot H de. 2000. Protection by glycine against hypoxic injury of rat
718 hepatocytes: inhibition of ion fluxes through nonspecific leaks. *J Hepatol* 32:58–66.
719 doi:10.1016/s0168-8278(00)80190-7
- 720 Gomes R, Guerra-Sá R, Arruda E. 2009. Coxsackievirus B5 induced apoptosis of HeLa cells:
721 effects on p53 and SUMO. *Virology* 396:256–63. doi:10.1016/j.virol.2009.10.005
- 722 Hamers AAJ, Dinh HQ, Thomas GD, Marcovecchio P, Blatchley A, Nakao CS, Kim C,
723 McSkimming C, Taylor AM, Nguyen AT, McNamara CA, Hedrick CC. 2019. Human
724 Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry. *Arteriosclerosis*
725 *Thrombosis Vasc Biology* 39:25–36. doi:10.1161/atvbaha.118.311022
- 726 Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, Tong C, Zha Y, Song Z, Gu G. 2020. Lactate
727 dehydrogenase, a Risk Factor of Severe COVID-19 Patients. *Medrxiv* 2020.03.24.20040162.
728 doi:10.1101/2020.03.24.20040162
- 729 Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, Decker T, Medzhitov R. 2013. Role of
730 Tissue Protection in Lethal Respiratory Viral-Bacterial Coinfection. *Science* 340:1230–1234.
731 doi:10.1126/science.1233632
- 732 Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. 2021. Fast gene
733 set enrichment analysis. *Biorxiv* 060012. doi:10.1101/060012
- 734 Li Shaohua, Jiang L, Li X, Lin F, Wang Y, Li B, Jiang T, An W, Liu S, Liu H, Xu P, Zhao L,
735 Zhang L, Mu J, Wang H, Kang J, Li Y, Huang L, Zhu C, Zhao S, Lu J, Ji J, Zhao J. 2020.
736 Clinical and pathological investigation of patients with severe COVID-19. *Jci Insight* 5.
737 doi:10.1172/jci.insight.138070
- 738 Li Shufen, Zhang Y, Guan Z, Li H, Ye M, Chen X, Shen J, Zhou Y, Shi Z-L, Zhou P, Peng K.
739 2020. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8
740 activation. *Signal Transduct Target Ther* 5:235. doi:10.1038/s41392-020-00334-0
- 741 Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amit I,
742 Zhang S, Zhang Z. 2020. Single-cell landscape of bronchoalveolar immune cells in patients
743 with COVID-19. *Nat Med* 26:842–844. doi:10.1038/s41591-020-0901-9
- 744 Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE,
745 Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang
746 H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier
747 JB, Campbell M, Odio CD, Casanovas-Massana A, Obaid A, Lu-Culligan A, Nelson A, Brito
748 A, Nunez A, Martin A, Watkins A, Geng B, Kalinich C, Harden C, Todeasa C, Jensen C, Kim
749 D, McDonald D, Shepard D, Courchaine E, White EB, Song E, Silva E, Kudo E, DeJuliis G,
750 Rahming H, Park H-J, Matos I, Nouws J, Valdez J, Fauver J, Lim J, Rose K-A, Anastasio K,
751 Brower K, Glick L, Sharma L, Sewanan L, Knaggs L, Minasyan M, Batsu M, Petrone M,
752 Kuang M, Nakahata M, Campbell M, Linehan M, Askenase MH, Simonov M, Smolgovsky
753 M, Sonnert N, Naushad N, Vijayakumar P, Martinello R, Datta R, Handoko R, Bermejo S,
754 Prophet S, Bickerton S, Velazquez S, Alpert T, Rice T, Khoury-Hanold W, Peng X, Yang Y,
755 Cao Y, Strong Y, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Cruz CD,

- 756 Farhadian S, Ko AI, Omer SB, Iwasaki A. 2020. Longitudinal analyses reveal immunological
757 misfiring in severe COVID-19. *Nature* 584:463–469. doi:10.1038/s41586-020-2588-y
- 758 Martins R, Carlos AR, Braza F, Thompson JA, Bastos-Amador P, Ramos S, Soares MP. 2019.
759 Disease Tolerance as an Inherent Component of Immunity. *Annu Rev Immunol* 37:405–437.
760 doi:10.1146/annurev-immunol-042718-041739
- 761 Michlewska S, Dransfield I, Megson IL, Rossi AG. 2008. Macrophage phagocytosis of apoptotic
762 neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-
763 inflammatory agents: key role for TNF-alpha. *Faseb J Official Publ Fed Am Soc Exp Biology*
764 23:844–54. doi:10.1096/fj.08-121228
- 765 Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. 2007. Identification of
766 Tim4 as a phosphatidylserine receptor. *Nature* 450:435–439. doi:10.1038/nature06307
- 767 Morioka S, Perry JSA, Raymond MH, Medina CB, Zhu Y, Zhao L, Serbulea V, Onengut-
768 Gumuscu S, Leitinger N, Kucenas S, Rathmell JC, Makowski L, Ravichandran KS. 2018.
769 Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release.
770 *Nature* 563:714–718. doi:10.1038/s41586-018-0735-5
- 771 Mulay A, Konda B, Garcia G, Yao C, Beil S, Villalba JM, Koziol C, Sen C, Purkayastha A,
772 Kolls JayK, Pociask DA, Pessina P, Aja JS de, Garcia-de-Alba C, Kim CF, Gomperts B,
773 Arumugaswami V, Stripp BR. 2021. SARS-CoV-2 infection of primary human lung
774 epithelium for COVID-19 modeling and drug discovery. *Cell Reports* 35:109055.
775 doi:10.1016/j.celrep.2021.109055
- 776 Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. *Nat*
777 *Rev Immunol* 11:723–737. doi:10.1038/nri3073
- 778 Mylvaganam S, Freeman SA, Grinstein S. 2021. The cytoskeleton in phagocytosis and
779 macropinocytosis. *Curr Biol* 31:R619–R632. doi:10.1016/j.cub.2021.01.036
- 780 Nagata S. 2018. Apoptosis and Clearance of Apoptotic Cells. *Annu Rev Immunol* 36:489–517.
781 doi:10.1146/annurev-immunol-042617-053010
- 782 Olagnier D, Lavergne R-A, Meunier E, Lefèvre L, Dardenne C, Aubouy A, Benoit-Vical F,
783 Ryffel B, Coste A, Berry A, Pipy B. 2011. Nrf2, a PPAR γ Alternative Pathway to Promote
784 CD36 Expression on Inflammatory Macrophages: Implication for Malaria. *Plos Pathog*
785 7:e1002254. doi:10.1371/journal.ppat.1002254
- 786 Park D, Han CZ, Elliott MR, Kinchen JM, Trampont PC, Das S, Collins S, Lysiak JJ, Hoehn KL,
787 Ravichandran KS. 2011. Continued clearance of apoptotic cells critically depends on the
788 phagocyte Ucp2 protein. *Nature* 477:220–4. doi:10.1038/nature10340
- 789 Parks BW, Black LL, Zimmerman KA, Metz AE, Steele C, Murphy-Ullrich JE, Kabarowski JH.
790 2013. CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following
791 bleomycin-induced lung injury[S]. *J Lipid Res* 54:1114–1123. doi:10.1194/jlr.m035352
- 792 Penberthy KK, Ravichandran KS. 2016. Apoptotic cell recognition receptors and scavenger
793 receptors. *Immunological reviews* 269:44–59. doi:10.1111/imr.12376
- 794 Peng Y, Elkon KB. 2011. Autoimmunity in MFG-E8-deficient mice is associated with altered
795 trafficking and enhanced cross-presentation of apoptotic cell antigens. *J Clin Invest*
796 121:2221–2241. doi:10.1172/jci43254
- 797 Perry JSA, Morioka S, Medina CB, Etchegaray JI, Barron B, Raymond MH, Lucas CD,
798 Onengut-Gumuscu S, Delpire E, Ravichandran KS. 2019. Interpreting an apoptotic corpse as
799 anti-inflammatory involves a chloride sensing pathway. *Nat Cell Biol* 21:1532–1543.
800 doi:10.1038/s41556-019-0431-1

- 801 Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. *Am J*
802 *Epidemiol* 27:493–497. doi:10.1093/oxfordjournals.aje.a118408
- 803 Ren X, Wen W, Fan X, Hou W, Su Bin, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He
804 Jiangping, Ma W, He Jingjing, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, Deng X,
805 Ding W, Feng Y, Gan R, Guo C, Guo W, He S, Jiang C, Liang J, Li Y, Lin J, Ling Y, Liu H,
806 Liu J, Liu N, Liu S-Q, Luo M, Ma Q, Song Q, Sun W, Wang G, Wang F, Wang Y, Wen X,
807 Wu Q, Xu G, Xie X, Xiong X, Xing X, Xu H, Yin C, Yu D, Yu K, Yuan J, Zhang B, Zhang
808 P, Zhang T, Zhao J, Zhao Peidong, Zhou J, Zhou W, Zhong S, Zhong X, Zhang S, Zhu L, Zhu
809 P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei J-X, Wei L, Bian X-
810 W, Liu X, Cheng T, Li X, Zhao Pingsen, Wang F-S, Wang H, Su Bing, Zhang Zheng, Qu K,
811 Wang X, Chen J, Jin R, Zhang Zemin. 2021. COVID-19 immune features revealed by a large-
812 scale single-cell transcriptome atlas. *Cell* 184:1895-1913.e19. doi:10.1016/j.cell.2021.01.053
- 813 Ren Y, Shu T, Wu D, Mu J, Wang C, Huang M, Han Y, Zhang X-Y, Zhou W, Qiu Y, Zhou X.
814 2020. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. *Cell Mol Immunol*
815 17:881–883. doi:10.1038/s41423-020-0485-9
- 816 Rodrigues TS, Sá KSG de, Ishimoto AY, Becerra A, Oliveira S, Almeida L, Gonçalves AV,
817 Perucello DB, Andrade WA, Castro R, Veras FP, Toller-Kawahisa JE, Nascimento DC, Lima
818 MHF de, Silva CMS, Caetite DB, Martins RB, Castro IA, Pontelli MC, Barros FC de, Amaral
819 NB do, Giannini MC, Bonjorno LP, Lopes MIF, Santana RC, Vilar FC, Auxiliadora-Martins
820 M, Luppino-Assad R, Almeida SCL de, Oliveira FR de, Batah SS, Siyuan L, Benatti MN,
821 Cunha TM, Alves-Filho JC, Cunha FQ, Cunha LD, Frantz FG, Kohlsdorf T, Fabro AT,
822 Arruda E, Oliveira RDR de, Louzada-Junior P, Zamboni DS. 2020. Inflammasomes are
823 activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity
824 in patients. *J Exp Med* 218. doi:10.1084/jem.20201707
- 825 Rodriguez-Manzanet R, Sanjuan MA, Wu HY, Quintana FJ, Xiao S, Anderson AC, Weiner HL,
826 Green DR, Kuchroo VK. 2010. T and B cell hyperactivity and autoimmunity associated with
827 niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. *Proc National*
828 *Acad Sci* 107:8706–8711. doi:10.1073/pnas.0910359107
- 829 Rothlin CV, Hille TD, Ghosh S. 2020. Determining the effector response to cell death. *Nat Rev*
830 *Immunol* 1–13. doi:10.1038/s41577-020-00456-0
- 831 Satyanarayanan SK, Kebir DE, Soboh S, Butenko S, Sekheri M, Saadi J, Peled N, Assi S,
832 Othman A, Schiff-Zuck S, Feuermann Y, Barkan D, Sher N, Filep JG, Ariel A. 2019. IFN- β is
833 a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation.
834 *Nat Commun* 10:3471. doi:10.1038/s41467-019-10903-9
- 835 Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, Krämer B,
836 Krammer T, Brumhard S, Bonaguro L, Domenico ED, Wendisch D, Grasshoff M, Kapellos
837 TS, Beckstette M, Pecht T, Saglam A, Dietrich O, Mei HE, Schulz AR, Conrad C, Kunkel D,
838 Vafadarnejad E, Xu C-J, Horne A, Herbert M, Drews A, Thibeault C, Pfeiffer M, Hippenstiel
839 S, Hocke A, Müller-Redetzky H, Heim K-M, Machleidt F, Uhrig A, Jarcy LB de, Jürgens L,
840 Stegemann M, Glösenkamp CR, Volk H-D, Goffinet C, Landthaler M, Wyler E, Georg P,
841 Schneider M, Dang-Heine C, Neuwinger N, Kappert K, Tauber R, Corman V, Raabe J, Kaiser
842 KM, Vinh MT, Rieke G, Meisel C, Ulas T, Becker M, Geffers R, Witzenzath M, Drost C,
843 Suttorp N, Kalle C von, Kurth F, Händler K, Schultze JL, Aschenbrenner AC, Li Y,
844 Nattermann J, Sawitzki B, Saliba A-E, Sander LE, (DeCOI) DC-19 OI, Angelov A, Bals R,
845 Bartholomäus A, Becker A, Bezdán D, Bonifacio E, Bork P, Clavel T, Colome-Tatche M,
846 Diefenbach A, Dilthey A, Fischer N, Förstner K, Frick J-S, Gagneur J, Goesmann A, Hain T,

- 847 Hummel M, Janssen S, Kalinowski J, Kallies R, Kehr B, Keller A, Kim-Hellmuth S, Klein C,
848 Kohlbacher O, Korbel JO, Kurth I, Landthaler M, Li Y, Ludwig K, Makarewicz O, Marz M,
849 McHardy A, Mertes C, Nöthen M, Nürnberg P, Ohler U, Ossowski S, Overmann J, Peter S,
850 Pfeffer K, Poetsch AR, Pühler A, Rajewsky N, Ralser M, Rieß O, Ripke S, Rocha UN da,
851 Rosenstiel P, Saliba A-E, Sander LE, Sawitzki B, Schiffer P, Schulte E-C, Schultze JL,
852 Szczyrba A, Stegle O, Stoye J, Theis F, Vehreschild J, Vogel J, Kleist M von, Walker A,
853 Walter J, Wieczorek D, Ziebuhr J. 2020. Severe COVID-19 Is Marked by a Dysregulated
854 Myeloid Cell Compartment. *Cell* 182:1419-1440.e23. doi:10.1016/j.cell.2020.08.001
- 855 Siddiqi HK, Mehra MR. 2020. COVID-19 Illness in Native and Immunosuppressed States: A
856 Clinical-Therapeutic Staging Proposal. *J Hear Lung Transplant*.
857 doi:10.1016/j.healun.2020.03.012
- 858 Silvin A, Chapuis N, Dunsmore G, Goubet A-G, Dubuisson A, Derosa L, Almiere C, Hénon C,
859 Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E,
860 Marin N, Szwebel T-A, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S,
861 Drubay D, Andrieu M, Lhonneur A-S, Saada V, Stoclin A, Willekens C, Pommeret F,
862 Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, Pène F, Gachot B,
863 André F, Zitvogel L, Ginhoux F, Fontenay M, Solary E. 2020. Elevated Calprotectin and
864 Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* 182:1401-
865 1418.e18. doi:10.1016/j.cell.2020.08.002
- 866 Tait JF, Smith C. 1999. Phosphatidylserine Receptors: Role of CD36 in Binding of Anionic
867 Phospholipid Vesicles to Monocytic Cells*. *J Biol Chem* 274:3048–3054.
868 doi:10.1074/jbc.274.5.3048
- 869 Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. 2011. Shedding of the Mer
870 Tyrosine Kinase Receptor Is Mediated by ADAM17 Protein through a Pathway Involving
871 Reactive Oxygen Species, Protein Kinase C δ , and p38 Mitogen-activated Protein Kinase
872 (MAPK). *J Biol Chem* 286:33335–33344. doi:10.1074/jbc.m111.263020
- 873 Trzebanski S, Jung S. 2020. Plasticity of monocyte development and monocyte fates. *Immunol*
874 *Lett* 227:66–78. doi:10.1016/j.imlet.2020.07.007
- 875 Valle DMD, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, Lavin Y,
876 Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Oekelen OV,
877 Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-
878 Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh
879 S, Merad M, Gnjjatic S. 2020. An inflammatory cytokine signature predicts COVID-19
880 severity and survival. *Nat Med* 26:1636–1643. doi:10.1038/s41591-020-1051-9
- 881 Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, Lima M de, Nascimento DC, Schneider
882 AH, Caetité D, Tavares LA, Paiva IM, Rosales R, Colón D, Martins R, Castro IA, Almeida
883 GM, Lopes MIF, Benatti MN, Bonjorno LP, Giannini MC, Luppino-Assad R, Almeida SL,
884 Vilar F, Santana R, Bollela VR, Auxiliadora-Martins M, Borges M, Miranda CH, Pazin-Filho
885 A, Silva LLP da, Cunha L, Zamboni DS, Dal-Pizzol F, Leiria LO, Siyuan L, Batah S, Fabro
886 A, Mauad T, Dolhnikoff M, Duarte-Neto A, Saldiva P, Cunha TM, Alves-Filho JC, Arruda E,
887 Louzada-Junior P, Oliveira RD, Cunha FQ. 2020. SARS-CoV-2-triggered neutrophil
888 extracellular traps mediate COVID-19 pathology. *J Exp Med* 217. doi:10.1084/jem.20201129
- 889 Wang Y, Subramanian M, Yurdagul A, Barbosa-Lorenzi VC, Cai B, Juan-Sanz J de, Ryan TA,
890 Nomura M, Maxfield FR, Tabas I. 2017. Mitochondrial Fission Promotes the Continued
891 Clearance of Apoptotic Cells by Macrophages. *Cell* 171:331-345.e22.
892 doi:10.1016/j.cell.2017.08.041

893 Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, Starr N, Buckel W, Grisel N,
894 Hummel E, Snow G, Morris D, Stenehjem E, Srivastava R, Brown SM. 2020. Clinical criteria
895 for COVID-19-associated hyperinflammatory syndrome: a cohort study. *Lancet*
896 *Rheumatology*. doi:10.1016/s2665-9913(20)30343-x
897 Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo
898 X, Yu G. 2021. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.
899 *Innovation* 2:100141. doi:10.1016/j.xinn.2021.100141
900 Yurdagul A, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK,
901 Rymond CC, Gerlach BD, Zheng Z, Kuriakose G, Kevil CG, Koomen JM, Cleveland JL,
902 Muoio DM, Tabas I. 2020. Macrophage Metabolism of Apoptotic Cell-Derived Arginine
903 Promotes Continual Efferocytosis and Resolution of Injury. *Cell Metab* 31:518-533.e10.
904 doi:10.1016/j.cmet.2020.01.001
905 Zhu N, Wang Wenling, Liu Z, Liang C, Wang Wen, Ye F, Huang B, Zhao L, Wang H, Zhou W,
906 Deng Y, Mao L, Su C, Qiang G, Jiang T, Zhao J, Wu G, Song J, Tan W. 2020.
907 Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial
908 cells. *Nat Commun* 11:3910. doi:10.1038/s41467-020-17796-z
909 Zuniga M, Gomes C, Carsons SE, Bender MT, Cotzia P, Miao QR, Lee DC, Rodriguez A. 2021.
910 Autoimmunity to Annexin A2 predicts mortality among hospitalised COVID-19 patients. *Eur*
911 *Respir J* 2100918. doi:10.1183/13993003.00918-2021
912 Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA,
913 Zuo M, Yadav V, Wang J, Woodard W, Lezak SP, Lugogo NL, Smith SA, Morrissey JH,
914 Kanthi Y, Knight JS. 2020. Prothrombotic autoantibodies in serum from patients hospitalized
915 with COVID-19. *Sci Transl Med* 12:eabd3876. doi:10.1126/scitranslmed.abd3876
916

917 **Figure captions**

918

919 **Figure 1. Macrophages engulf apoptotic cells carrying viable SARS-CoV-2**

920 **(A)** Immunoblot of caspase-8 and caspase-3 cleavage in Calu-3 and Vero CCL81 cells in response
921 to infection with SARS-CoV-2 for 48 h (CoV2, detected with rabbit anti-Spike), UV irradiation
922 (UV) or freezing and thawing (F/T).

923 **(B)** Flow cytometric analysis of caspase-3 cleavage (Cl-caspase-3) in Calu-3 cells unstimulated
924 (Cntl) or infected with CoV2 for 48 h. The pan-caspase inhibitor z-VAD-FMK (zVAD; 20 μ M)
925 or vehicle (DMSO) were added to cell cultures after viral adsorption. Representative histogram,
926 geometric mean fluorescence intensity (MFI), and frequency of Cl-caspase-3⁺ cells (gated on Total

927 cells/Single cells) are shown. The black line on the histogram represents the control sample labeled
928 with secondary antibody only.

929 **(C)** Flow cytometric analysis of apoptosis in Vero CCL81 cells in response to UV light irradiation
930 or 48 h post-infection with CoV2, assessed by annexin V (FITC) and viability dye (Zombie NIR)
931 co-staining. Representative histogram and frequency of each population (pre-gated on Total
932 cells/Single cells) are shown.

933 **(D)** Cytotoxicity analysis by measurement of lactate dehydrogenase (LDH) release on the
934 supernatants of Vero CCL81 cells in response to UV light irradiation or 48 h post-infection with
935 CoV2.

936 **(E, F)** Representative histological findings in post-mortem lung tissue from COVID-19 patients
937 obtained by ultrasound-guided minimally invasive autopsy. **(E)** Immunofluorescence images of
938 tissue samples labeled with anti-CI-caspase-3 (red), anti-dsRNA (green), and stained with Hoechst
939 (nuclei, blue) for the detection of caspase-3 activation in infected epithelia (COVID-19, bottom
940 panels) compared to samples from control patients (Ctrl, upper panels). Tissues were scanned by
941 wide-field epifluorescence imaging. Scale bar: 20 μ m, asterisks: erythrocytes. The mean
942 fluorescence intensity (MFI) of CI-caspase-3 of at least 300 cells are shown (n = 3 individuals per
943 group). Technical control for secondary antibodies background is shown in Figure S1A. **(F)**
944 Representative immunofluorescence image of a COVID-19 patient tissue sample labeled for the
945 detection of efferocytosis in situ and superimposed with differential interference contrast. Samples
946 were labeled with anti-CD68 (detecting macrophages, green), anti-cytokeratin18 (CK-18,
947 detecting epithelial cells, white), anti-Spike (detecting SARS-CoV-2, red), and stained with
948 Hoechst (nuclei, blue). Bottom panels show higher magnification of (a, b) CD68⁺ macrophage
949 with CK-18 and Spike labeling in the cytosol and (c) CD68⁺ only macrophage. White arrows: CK-

950 18⁺ cells; asterisks: erythrocytes. Tissues were scanned by wide-field epifluorescence imaging.

951 Scale bar: 20 μm ; scale bar for insets: 10 μm .

952 **(G)** Quantification by TCID₅₀ of SARS-CoV-2 viral loads in Vero CCL81 cells infected for 48 h.

953 Viral loads were estimated for pre-sorted (Total cells) or annexin V⁺ (Ann⁺ cells) cells isolated by

954 magnetic separation.

955 **(H)** Uptake of apoptotic Vero CCL81 cells (labeled with CTFR) in response to UV irradiation

956 (UV-AC) or infection with SARS-CoV-2 for 48 h (Cov2-AC) by human monocyte-derived

957 macrophages (labeled with CTV). Macrophages were co-incubated with AC for 2 h, and

958 internalization was assessed by flow cytometry. Representative plot and percentage of engulfment

959 (gated on Total cells/Single cells/Live cells/CTV⁺/CTV⁺CTFR⁺ cells) are shown.

960 Boxes represent the mean of five (B, D), four (C, H), or three (G) biological replicates, and error

961 bars are \pm S.E.M. Each biological replicate is shown as a circle. Significance was calculated by

962 ANOVA (B-D), Mann-Whitney test (E) or Student's test (G, H). *, p<0.05, **, p<0.001, ***,

963 p<0.0001, comparing the indicated groups. Data shown are from one representative out of two (A,

964 C, G) or three (B, D, H) experiments performed independently with similar results.

965

966 **Figure 1 – figure supplement 1. Support data for Figure 1.**

967 **(A).** Immunofluorescence images of tissue samples immunolabeled with secondary antibodies-

968 only used for detection anti-cleaved Caspase-3 (red, anti-rabbit IgG conjugated to Alexa 594),

969 anti-dsRNA (green, donkey anti-mouse IgG F(ab)²-Alexa 488), and stained with Hoechst (nuclei,

970 blue) in Figure 1E. Tissues were scanned by wide-field epifluorescence imaging. Scale bar: 20

971 μm , asterisks: erythrocytes.

972 **(B)** TCID₅₀ quantification of SARS-CoV-2 viral loads from detached, apoptotic Calu-3 and Vero
973 CCL81 cells (CoV2-AC, 1.0 x 10⁶ cells) and their cell-free supernatants, collected 48 h post-
974 infection and isolated as described in the Methods.

975 **(C)** Uptake of apoptotic Calu-3 and Vero CCL81 cells (labeled with CFSE) in response to UV
976 irradiation (UV-AC) or infection with SARS-CoV-2 for 48 h (CoV2-AC) by THP-1-derived
977 macrophages (labeled with CTFR). Macrophages were co-incubated with AC for 2 h, and
978 internalization was assessed by flow cytometry. Representative gating strategy, plots, and
979 percentage of engulfment (gated on Total cells/Single cells/Live cells/CTFR⁺/CTFR⁺ CFSE⁺ cells)
980 are shown.

981 **(D)** Representative maximal projection of scanning confocal images showing the uptake of UV-
982 AC or CoV2-AC (from Vero CCL81 cells, CFSE-labeled, green) by human monocyte-derived
983 macrophages after 2 h of co-incubation. Samples were stained with Hoechst (nuclei, blue) and
984 were immunolabeled with anti-Spike (SARS-CoV-2, red) and anti-CD11b (macrophage, white).
985 Scale bar: 5 μm.

986 **(E)** Human monocyte-derived macrophages or THP-1-derived macrophages were unstimulated
987 (Cntrl), co-incubated with apoptotic Vero CCL81 cells isolated from UV-irradiated (UV-AC) or
988 SARS-CoV-2-infected (CoV2-AC) cultures, stimulated with the supernatants of infected apoptotic
989 cells (CoV2-AC Sup), or infected with SARS-CoV-2 (CoV2), as indicated. The percentage of
990 cellular viability was measured using a viability probe 24 h post-stimulation and analysis by flow
991 cytometry (gated on Total cells/Single cells).

992 Boxes represent the mean of three biological replicates, and error bars are ± S.E.M. Each biological
993 replicate is shown as a circle. Significance was calculated by Student's test (B-C) or ANOVA (E).

994 *, p<0.05, **, p<0.001, ***, p<0.0001, comparing the indicated groups; ns: non-significant. Data

995 shown are from one representative out of two (B, C) or three (E) experiments performed
996 independently with similar results.

997

998 **Figure. 2. Engulfment of SARS-CoV-2-infected dying cells impairs macrophage anti-**
999 **inflammatory functions.**

1000 Macrophages were unstimulated (Cntrl), co-incubated with apoptotic Vero CCL81 cells (AC)
1001 isolated from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, stimulated
1002 with the supernatants of infected apoptotic cells (CoV2-AC Sup), or infected with CoV2 (CoV2),
1003 as indicated.

1004 **(A)** Heatmap showing the expression of M2-marker genes (*CCL18*, *MRC1*, *MMP9*, *PPARG*, and
1005 *CDI63*) in human monocyte-derived macrophages 24 h after stimulation, calculated as log₂ fold
1006 change relative to Cntrl. mRNA expression was determined by RT-qPCR and normalized to
1007 *GAPDH*. Data represent the mean of biological triplicates.

1008 **(B)** Flow cytometric analysis of CD206 expression on the cell surface of human monocyte-derived
1009 macrophages (gated on Total cells/Single cells/Live cells; gating strategy in Figure 2 – figure
1010 supplement 1A) 24 h after stimulation. Representative histograms and quantification of geometric
1011 mean fluorescence intensity (MFI) are shown. The black line on the histogram represents FMO
1012 control.

1013 **(C-E)** Flow cytometric analysis of CD206 expression on the cell surface of THP1-derived
1014 macrophages 24 h after stimulation, showing quantification of CD206 MFI. **(C)** Macrophages
1015 (labeled with CTFR) were stimulated with UV-AC or CoV2-AC (labeled with CTV) and CD206
1016 expression was measured on macrophages that engulfed (+) or not (-) AC. Gating strategy is
1017 depicted in Figure 2- figure supplement 1E. **(D)** Where indicated, isolated CoV2-AC were UV-

1018 irradiated for 20 min prior to co-incubation for viral inactivation. **(E)** The responses of
1019 macrophages to UV-AC and CoV2-AC were compared to infection with CoV2 in the presence of
1020 UV-AC (UV-AC + CoV2).

1021 Boxes represent the mean of three biological replicates using cells from a single donor (A, B) or
1022 THP-1-derived cells (C-E), and error bars are \pm S.E.M. Each biological replicate is shown as a
1023 circle. Significance was calculated by ANOVA. *, $p < 0.05$, **, $p < 0.001$, ***, $p < 0.0001$, comparing
1024 the indicated groups. Data shown are from one representative out of at least two experiments
1025 performed independently with similar results.

1026

1027 **Figure 2 – figure supplement 1. Support data for Figure 2.**

1028 **(A)** Representative gating strategy used to determine the CD206 expression on the surface of
1029 macrophages in response to the different stimulus by flow cytometry (backgating corresponds to
1030 FMO control showed in Figure 2B).

1031 **(B)** THP-1-derived macrophages were unstimulated (Cntrl), co-incubated with UV-AC, CoV2-
1032 AC, or CoV2-AC Sup obtained from Vero CCL81 cells, or infected with CoV2, as indicated.
1033 Expression of *MRC1* in macrophages showed as fold change relative to Cntrl was assessed 24 h
1034 after stimulation. mRNA expression was determined by RT-qPCR and normalized to *GAPDH*.

1035 **(C-D)** THP-1-derived macrophages were incubated with UV-AC, Cov2-AC, or CoV2-Sup
1036 obtained from **(C)** Calu-3 or **(D)** Vero CCL81 infected cell cultures. CD206 expression on the cell
1037 surface 24h after stimulation was assessed by flow cytometry (gated on Total cells/Single
1038 cells/Live cells). Representative histograms and quantification of geometric mean fluorescence
1039 intensity (MFI) of CD206 are shown.

1040 (E) Representative gating strategy used to determine the CD206 expression on the surface of
1041 CTFR-labeled macrophages stimulated with CTV-labeled AC in Figure 2C.

1042 (F) Quantification by TCID₅₀ of the SARS-CoV-2 viral loads in 1.0×10^6 AC isolated from Vero
1043 CCL81 infected cells, either intact (CoV2-AC) or UV-irradiated for 20 min for viral inactivation
1044 (CoV2-AC UV).

1045 Boxes represent the mean of three biological replicates, and error bars are \pm S.E.M. Each biological
1046 replicate is shown as a circle. Significance was calculated by ANOVA (B-D) *, $p < 0.05$, **, $p < 0.001$,
1047 ***, $p < 0.0001$, comparing the indicated groups; ns: non-significant. Data shown are from
1048 one representative out of two experiments performed independently with similar results.

1049

1050 **Figure. 3. Engulfment of SARS-CoV-2-infected dying cells causes inflammatory cytokine**
1051 **production**

1052 Macrophages were unstimulated (Cntrl), co-incubated with apoptotic Vero CCL81 cells (AC)
1053 isolated from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, stimulated
1054 with the supernatants of infected apoptotic cells (CoV2-AC Sup), or infected with CoV2, as
1055 indicated.

1056 (A) *IL6* expression in primary human monocyte-derived macrophages 24 h after stimulation
1057 showed as fold change relative to Cntrl. mRNA expression was determined by RT-qPCR and
1058 normalized to GAPDH.

1059 (B) CBA quantification of IL-6 and IL-1 β in the culture supernatants of the monocyte-derived
1060 macrophages 24 h after stimulation.

1061 (C, D) ELISA quantification of IL-6 in the culture supernatants of THP1-derived macrophages 24
1062 h after stimulation. (C) Macrophages were stimulated with early apoptotic AC (Annexin V⁺

1063 Zombie⁻) or late apoptotic AC (Annexin V⁺ Zombie⁺) sorted out by flow cytometry. **(D)** Where
1064 indicated, isolated CoV2-AC were UV-irradiated (UV) for 20 min or fixed with 2%
1065 paraformaldehyde (Fix) for 10 min prior to co-incubation.

1066 **(E-H)** ELISA quantification of IL-6 in the culture supernatants of human primary monocyte-
1067 derived macrophages 24 h after stimulation. **(E)** IL-6 secretion in response to CoV2-AC was
1068 compared to apoptotic cells isolated from Vero CCL81 cells similarly infected with
1069 Coxsackievirus (Coxsackie-AC). **(F)** PtdSer on the surface of CoV2-AC was blocked by
1070 incubation with Annexin V (Ann, 0.1 µg/mL) prior to addition to macrophage cultures to inhibit
1071 AC binding. **(G)** CoV2-AC and macrophages were co-incubated in the presence of Cytochalasin
1072 D (Cyto D, 10 µM) to inhibit AC internalization. **(H)** Macrophages were treated with Remdesivir
1073 (Remd, 20 µM) following stimulation with CoV2-AC to inhibit viral RNA transcription.

1074 Boxes represent the mean of three biological replicates using cells from a single donor (A, B, F,
1075 G), two donors (E), or THP-1-derived cells (C, D), and error bars are ± S.E.M. Each biological
1076 replicate is shown as a circle. Significance was calculated by ANOVA. *, p<0.05, **, p<0.001,
1077 ***, p<0.0001, comparing the indicated groups. Data shown are from one representative out of at
1078 least two experiments performed independently with similar results.

1079

1080 **Figure 3 – figure supplement 1. Support data for Figure 3.**

1081 **(A)** THP-1-derived macrophages were incubated with UV-AC, Cov2-AC, or CoV2-Sup obtained
1082 from infected Vero CCL81 cells or infected with CoV2. Expression of *IL6* in macrophages showed
1083 as fold change relative to Cntrl was assessed 24h after stimulation. mRNA expression was
1084 determined by RT-qPCR and normalized to *GAPDH*.

1085 **(B-C)** THP-1-derived macrophages were incubated for 24 h with UV-AC, Cov2-C, or CoV2-Sup
1086 obtained from Calu-3 or Vero CCL81 infected cell cultures, as indicated. **(B)** IL-6 and **(C)** IL-1 β
1087 in the culture supernatants were quantified by CBA.

1088 **(D)** ELISA quantification of IL-6 in the culture supernatants of THP-1-derived macrophages
1089 incubated with UV-AC obtained from Vero CCL81 cells infected in the presence of glycine (Gly,
1090 5 mM), where indicated, to inhibit release of cytosolic content due to permeabilization.

1091 **(E)** Quantification by TCID₅₀ of the viral loads in 1.0×10^6 AC isolated from Vero CCL81 cells
1092 similarly infected with either Coxsackie virus (Coxsackie-AC) or SARS-CoV-2 (CoV2-AC).

1093 **(F)** ELISA quantification of IL-6 in the culture supernatants of THP-1-derived macrophages
1094 stimulated with Cov2-AC for 24 h. PtdSer on the cell surface was blocked to inhibit AC binding
1095 by incubation of CoV2-AC with Annexin V (Ann, 0.01 and 0.1 $\mu\text{g}/\text{mL}$) prior to addition to
1096 macrophage cultures.

1097 Boxes represent the mean of three (A, B, C, F) or four (D, E) biological replicates, and error bars
1098 are \pm S.E.M. Each biological replicate is shown as a circle. Significance was calculated by
1099 ANOVA (A-D, F) or Student's test (E), *, $p < 0.05$, **, $p < 0.001$, ***, $p < 0.0001$, comparing the
1100 indicated groups; ns: non-significant. Data shown are from one representative out of two
1101 experiments performed independently with similar results.

1102

1103 **Figure 4. Engulfment of SARS-CoV-2-infected dying cells suppresses continual efferocytosis**
1104 **by macrophages**

1105 **(A)** Expression of efferocytic receptors in human primary monocyte-derived macrophages.
1106 Macrophages were unstimulated (Cntrl), co-incubated for 24 h with apoptotic Vero CCL81 cells
1107 (AC) isolated from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, or

1108 infected with CoV2 (CoV2), as indicated. Expression of *CD36*, *SRA1*, *ITGB5*, *TIMD4*, and
1109 *MERTK* are showed as fold change relative to Cntrl. mRNA levels were determined by RT-qPCR
1110 and normalized to *GAPDH*.

1111 **(B-F)** Flow cytometric analysis of two-step efferocytosis *in vitro*. THP-1-derived macrophages
1112 (CTV-labeled) were incubated with UV-AC or CoV2-AC isolated from Vero CCL81 cell cultures
1113 (labeled with pHRodo) for 18 h, and subsequently incubated with UV-irradiated apoptotic Jurkat
1114 cells (UV-Jurkat, CTFR-labeled) for 2 h. **(B)** Schematic representation of consecutive co-
1115 incubations of THP-1-derived macrophages with apoptotic cells prior to the assessment of cell
1116 corpse uptake by flow cytometry. **(C)** Representative maximal projection of scanning confocal
1117 images showing the uptake of AC (pHRodo) and UV-Jurkat (CTFR) by macrophages (CTV) after
1118 consecutive co-incubations. **(D)** Percentage of macrophages with internalized UV-AC or CoV2-
1119 AC (gated on Total cells/Single cells/Live cells/CTV⁺/CTV⁺ pHRodo⁺); gating strategy is
1120 displayed in Figure 4- figure supplement 1B). **(E)** Percentage of macrophages that engulfed UV-
1121 Jurkat within pHRodo⁺ populations (gated on Total cells/Single cells/Live cells/ CTV⁺/pHRodo⁺/
1122 pHRodo⁺ CTFR⁺). **(F)** Percentage of macrophages that engulfed UV-Jurkat within pHRodo⁺
1123 populations (gates as in (E)) wherein macrophages were treated with Remdesivir (Remd, 20 μ M)
1124 following stimulation with CoV2-AC.

1125 Boxes represent the mean of three (A) or four (D-F) biological replicates using cells from a single
1126 donor in (A) or THP-1-derived macrophages (D-F), and error bars are \pm S.E.M. Each biological
1127 replicate is shown as a circle. Significance was calculated by ANOVA (A, F) or Student's test (D,
1128 E). *, p<0.05, **, p<0.001, ***, p<0.0001, comparing the indicated groups. Data shown are from
1129 one representative out of three experiments performed independently with similar results.

1130

1131 **Figure 4 – figure supplement 1. Support data for Figure 4.**

1132 (A) THP-1-derived macrophages were incubated with UV-AC or CoV2-AC obtained from
1133 infected Vero CCL81 cells or infected with CoV2. Expression of the efferocytic receptors *CD36*,
1134 *SRA-I*, *ITGB5*, *TIMD4*, and *MERTK* showed as fold change relative to Cntrl was assessed 24 h
1135 after stimulation. mRNA levels were determined by RT-qPCR and normalized to *GAPDH*.

1136 (B) Representative gating strategy used to determine CTV-labeled macrophage populations for the
1137 two-step efferocytosis experiment showed in Figures 4D and E.

1138 (C) THP-1-derived macrophages (CTV-labeled) were infected or not with SARS-CoV-2 (CoV2)
1139 for 18 h and subsequently were incubated with CTFR-labeled, UV-irradiated apoptotic Jurkat cells
1140 (UV-Jurkat) for 2 h. UV-Jurkat uptake is shown as the percentage of CTFR⁺ (gated on Total
1141 cells/Single cells/Live cells/ CTV⁺/ CTV⁺ CTFR⁺).

1142 Boxes represent the mean of three biological replicates, and error bars are \pm S.E.M. Each biological
1143 replicate is shown as a circle. Significance was calculated by ANOVA (A) or Student's test (C).
1144 *, $p < 0.05$, **, $p < 0.001$, ***, $p < 0.0001$ comparing the indicated groups; ns: non-significant. Data
1145 shown are from one representative out of at least two experiments performed independently with
1146 similar results.

1147

1148 **Figures 5. Lung monocytes and macrophages of severe COVID-19 patients express reduced**
1149 **levels of efferocytic receptors.**

1150 (A-B) Representative histological findings in post-mortem lung tissue from control patients (Cntrl)
1151 and COVID-19 patients, obtained by ultrasound-guided minimally invasive autopsy. Tissue
1152 samples were immunolabeled with anti-S100A9 (phagocytes, green), (A) anti-CD36 (red), or (B)
1153 anti-MERTK (red) and stained with DAPI (nuclei, blue). Representative images show cropped

1154 details of lung tissues scanned by wide-field epifluorescence imaging. Scale bar: 10 μm . The mean
1155 fluorescence intensity (MFI) of CD36 and MERTK of at least 300 S1009⁺ cells are shown (n = 6
1156 control and 4 COVID-19 patient samples). Dots represent an S1009⁺ cell (A and B), the crossing
1157 line represents the mean, and error bars are \pm S.E.M. Significance was calculated by Mann-
1158 Whitney test (A and B), *, p<0.05, **, p<0.001, ***, p<0.0001, comparing the indicated groups.
1159 **(C)** GSEA analysis for efferocytosis-related gene sets in early-infiltrating phagocytes (S1009⁺
1160 CCL18⁻) and in anti-inflammatory monocytes-derived macrophages (CD14⁺ S11009⁻ CCL18⁺)
1161 clusters from the bronchoalveolar lavage of mild (M) and severe (S) COVID-19 patients versus
1162 healthy individuals. The corrplot depicts the normalized enrichment score (NES), and p value for
1163 the gene sets indicated on the y axis.
1164 **(D)** Enriched efferocytosis-related Gene Ontology (GO) terms in genes repressed in virus-positive
1165 versus virus-negative alveolar macrophages.

1166

1167 **Supplementary File 1.** Custom gene sets incorporating associated to efferocytic pathway and
1168 related to human diseases (related to Figure 5C).

1169

1170 **Supplementary File 2.** Medical characteristics of COVID-19 patients.

1171

1172


1173

1174


1175

1176


Figure 1




A




B



C



D



E







Figure 2


















Figure 4







A



B



C



Supplementary File 1. Custom gene sets incorporating genes associated to efferocytic pathways and related to human diseases (Penberthy and Ravichandran, 2016; Boada-Romero et al., 2020) (related to Figure 4C).

Term	Gene				
Recognition (eat-me receptors)	GAS6	SCARB1	MARCO	MEGF10	STAB1
	MERTK	ITGB3	MFGE8	MSR1	STAB2
	ADGRB1	ITGAV	AXL	TIMD4	AGER
	LRP1	CD36	TYRO3	C1QA	SCARF1
Engulfment and processing	RAC2	RHOBTB1	DNM1L	ABCA1	ATG7
	RAC1	RHOG	ELMO1	RUBCN	ATG16L1
	RHOH	RAB14	SLC2A1	BECN1	GULP
	TREX1	TYROBP	SLC12A4	PIK3C3	
	RHOBTB2	DOCK1	DNASE2	ATG5	

Supplementary File 2 - COVID-19 patients medical characteristics

	Demographics	%
Number	4	
Age	73.5 ± 7.7	
Female		50
Comorbidities		
Hypertension	2	50
Obesity	1	25
Diabetes	2	50
History of smoking	1	25
Heart disease	3	75
Laboratorial findings		
ALT (U/L)*	620.25 ± 1106.36	
AST (U/L)**	1234 ± 2278.72	
CRP (mg/dL)***	14.37 ± 5.04	
D-Dimers (µg/mL)#	2.38 ± 1.45	
LDH (mmol/L)##	3.05 ± 1.85	
Urea (mg/dL)###	147.45 ± 35.68	
Respiratory status		
Mechanical ventilation	3	75
Nasal-cannula oxygen	3	75
pO2	72.65 ± 13.53	
SatO2	90.2 ± 7.2	
Disease severity		
Mild	0	0
Moderate	0	0
Severe	4	100
Outcome		
Death	4	0

*ALT: Alanine Transaminase (normal range 10-49 U/L);

**AST: Aspartate Aminotransferase (normal value <32 U/L);

***CRP: C-reactive protein (normal value <1.0 mg/dL);

#D-dimers (normal value <0.5µg/mL);

##LDH: Lactate Dehydrogenase (normal range 120-246 U/L);

###Urea (normal range 19-49 mg/dL);